Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | Director · Chief Executive Officer | June 30, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivos Therapeutics, Inc.
Report date June 30, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Preferred StockSEC Table I · non-derivative | IndirectSee footnote | 85,910 |
Reported balance
After 2026-06-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-06-30 · Other · Acquired 85,910 · Balance 85,910 F2: On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2031-06-30 | IndirectSee footnote | 85,910 |
Reported balance
After 2026-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-30 · Other · Acquired 85,910 · Balance 85,910 F2: On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 3,461 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,461 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 69,600 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 69,600 F1: Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Expires 2027-02-25 | Direct | 359,754 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 359,754 F3: Represents employee stock options granted on various dates, with exercise prices ranging from $2.38 to $81.75 and expiration dates ranging from February 25, 2027 to September 7, 2034, and also reflects the expiry of 5,001 stock options granted June 16, 2021 that were previously reported on the Reporting Person's Form 4 filed on November 27, 2024, which expired unexercised on June 26, 2026. Table II reports the earliest expiration dates (02/25/2027). |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.
F2: On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein.
F3: Represents employee stock options granted on various dates, with exercise prices ranging from $2.38 to $81.75 and expiration dates ranging from February 25, 2027 to September 7, 2034, and also reflects the expiry of 5,001 stock options granted June 16, 2021 that were previously reported on the Reporting Person's Form 4 filed on November 27, 2024, which expired unexercised on June 26, 2026. Table II reports the earliest expiration dates (02/25/2027).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Sep 18, 2026 21:04 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | OtherWarrant (Right to Buy) · Derivative | 85,910 | $0.58 Strike: $0.46 | $49,999.62 |
DisclosureSEC source: 0001493152-26-043383 · ownership.xml · derivative · entry 4 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 85,910 Underlying: Common Stock · 85,910 shares Expires 2031-06-30 F2 · ownership.nature: On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2026 Filed Sep 18, 2026 21:04 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | OtherPreferred Stock | 85,910 | $0.58 | $49,999.62 |
DisclosureSEC source: 0001493152-26-043383 · ownership.xml · nonDerivative · entry 3 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 85,910 F2 · ownership.nature: On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:47 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 315,421 | $2.64 Strike: $2.64 | $832,711.44 |
DisclosureSEC source: 0001493152-24-048026 · ownership.xml · derivative · entry 3 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,755 Underlying: Common Stock · 315,421 shares Expires 2034-09-07 F2 · derivative.exercise_date: On September 7, 2024 (the "Grant Date"), the Reporting Person received a grant of 315,421 stock options, which grant was made under but subject to stockholder approval of the Issuer's 2024 Omnibus Equity Incentive Plan and such grant at the Issuer's 2024 Annual Meeting. Such meeting was held, and such stockholder approval was obtained, on November 26, 2024. One-third shall vest and become exercisable in three installments on each of the first, second and third anniversaries of the date of grant through September 7, 2027. Read SEC document |
| June 20, 2024 Filed Jun 29, 2024 00:53 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $2.38 Strike: $2.38 | $47,600.00 |
DisclosureSEC source: 0001493152-24-025688 · ownership.xml · derivative · entry 3 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,334 Underlying: Common Stock · 20,000 shares Expires 2029-06-20 F2 · derivative.exercise_date: On June 20, 2024 (the "Grant Date"), the Reporting Person received a grant of 20,000 stock options from the Issuer. One-fifth vested immediately and one-fifth will vest annually on each anniversary of the Grant Date through June 20, 2028. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 01:58 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 14,000 | $0.53 | $7,420.00 |
DisclosureSEC source: 0001493152-23-021910 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,521 Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 10:10 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 5,000 | $0.53 | $2,650.00 |
DisclosureSEC source: 0001493152-23-021751 · ownership.xml · nonDerivative · entry 3 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,521 Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 10:10 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 10,000 | $0.54 | $5,400.00 |
DisclosureSEC source: 0001493152-23-021751 · ownership.xml · nonDerivative · entry 2 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,521 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 10:10 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 21 | $0.50 | $10.50 |
DisclosureSEC source: 0001493152-23-021751 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,521 Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 23:15 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 10,000 | $0.49 | $4,900.00 |
DisclosureSEC source: 0001493152-23-021525 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 02:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.48 Strike: $0.48 | $72,000.00 |
DisclosureSEC source: 0001493152-22-036727 · ownership.xml · derivative · entry 4 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,334 Underlying: Common Stock · 483,334 shares Expires 2027-12-23 F3 · derivative.exercise_date: 150,000 stock options granted on December 23, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through December 23, 2026. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 02:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 333,334 | $0.48 Strike: $0.48 | $160,000.32 |
DisclosureSEC source: 0001493152-22-036727 · ownership.xml · derivative · entry 3 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,334 Underlying: Common Stock · 333,334 shares Expires 2027-12-23 F2 · derivative.exercise_date: 333,334 fully vested stock options granted on December 23, 2022. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 02:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 20,000 | $0.50 | $10,000.00 |
DisclosureSEC source: 0001493152-22-036727 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 F1 · price: Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 10:08 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 4,000 | $1.83 | $7,320.00 |
DisclosureSEC source: 0001493152-22-015773 · ownership.xml · nonDerivative · entry 2 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Read SEC document |
| May 31, 2022 Filed Jun 3, 2022 10:08 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 8,000 | $2.03 | $16,240.00 |
DisclosureSEC source: 0001493152-22-015773 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 23:54 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $3.27 Strike: $3.27 | $408,750.00 |
DisclosureSEC source: 0001493152-22-005662 · ownership.xml · derivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-02-25 F1 · derivative.exercise_date: 125,000 stock options granted on February 25, 2022. One-fifth vested immediately and one-fifth vests annually on each anniversary date through February 25, 2026. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 19:09 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 5,000 | $4.31 | $21,550.00 |
DisclosureSEC source: 0001493152-21-023354 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 19:47 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 5,000 | $3.00 | $15,000.00 |
DisclosureSEC source: 0001493152-21-020536 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Read SEC document |
| June 16, 2021 Filed Feb 15, 2022 02:21 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $5.64 Strike: $5.64 | $705,000.00 |
DisclosureSEC source: 0001493152-22-004603 · ownership.xml · derivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2026-06-26 F1 · derivative.exercise_date: An option for the purchase of 125,000 shares was granted on June 16, 2021. The option vests one fifth immediately and one-fifth annually on each anniversary date through June 16, 2025. Read SEC document |
| May 25, 2021 Filed May 26, 2021 01:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 4,000 | $5.38 | $21,520.00 |
DisclosureSEC source: 0001493152-21-012901 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.335 to $5.40. Read SEC document |
| December 23, 2020 Filed Dec 23, 2020 23:53 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 1,000 | $7.27 | $7,266.90 |
DisclosureSEC source: 0001493152-20-024277 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · ownership.direct: 1,000 shares purchased in prices ranging from $7.25 through $7.2798 per share. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 13:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | PurchaseCommon Stock | 500 | $8.50 | $4,250.00 |
DisclosureSEC source: 0001493152-20-023466 · ownership.xml · nonDerivative · entry 1 Huntsman Ronald Kirk · CIK 0001835498 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.